Welcome to Ventana Biotech Possible scam be careful!!!!!!
http://www.ventanabiotech.com
Ventana Biotech is a early stage biotech company focused on IP discovery and product licensing.
Our mission at Ventana Biotech Inc is to invent innovative intellectual property for medicated chewing gum in the areas of appetite suppressants and stress management and we seek to bring these products to market through partnering with manufactures of medicated chewing gum and other medicated
Ventana Biotech Inc strives to improve the health and quality of life for the average person by eventually making its medicated chewing gum available for over-the-counter sales through partnering up with companies that has already these manufacturing and distribution channels in place. Our strategy is to build on anticipated success of what will be our flagship products and continue to research new areas of opportunities.
Ventana Biotech inc strategy
Ventana Biotech Inc strives to improve the health and quality of life for patients, develop breakthrough treatment options for physicians, offer rewarding careers to employees, and deliver value to our shareholders. Our strategy is to build on anticipated success of what will be our flagship product and continue to invest in new targets as well as R&D in obesity to provide longer-term growth.
Ventana has evolved to become a scientifically strong early stage biotech company that is focused on disease areas that impact 1 in 5 people in the world. Our team is dedicated to the discovery and development of targeted therapies to revolutionize the way obesity is treated and improve treatment outcomes.
Our obesity team is dedicated to the discovery and development of novel drugs for the treatment of type 2 diabet and obesity. The strategy for this business team is to advance a pipeline of innovative diabetes and obesity research projects through clinical proof-of-concept studies, with a view to then potentially seeking financially attractive development and commercialization partnerships for these research programs.
Our goal is to pave the way for the future of diabetes and obesity treatments. We believe that our Company strategy is poised to deliver a rich pipeline of promising drug candidates that have the potential to significantly improve the treatment options available to patients today.
Product
Ventana Biotech Inc’s main focus is the development of an appetite suppressing chewing gum or if higher dosages are needed in the form of an injection. The idea behind the product trying to emulate the body's natural signals for feeling full using a drug based on a natural gut hormone produced after every meal.
It is likely to be developed as an injectable drug first but our main focus is to take the product to the stage of eventually be taken orally and incorporated into a gum.
Ventana is not looking at a toxic drug, which has all sorts of side effects. Ventana is looking at the body's own way of switching off appetite after a meal.
In the western world, more than a 20% of adults are obese and of the remaining population half of men and a third of women are classified as overweight and early indications shows that the drug is able to reduce appetite with between 15% to 25%.
Drugs to tackle obesity often have unpleasant side effects, Ventana’s aim is to create a drug that will be free of side effects because it already circulates in the body. The body produces the hormone after every meal to ensure eating does not run out of control. There is evidence that some people have more of the hormone than others, and becoming overweight reduces the levels produced.
Licensing |
| Ventana Biotech Inc aims at establishing partnerships with major biotech and pharmaceutical companies for the late development phases and for the regulatory approval process and subsequent commercialization of our products.
Ventana has several projects in different stages of development within serious diseases with significant unmet medical needs such as: - Type 2 diabetes
- Obesity
-
 Anti-Obesity and Diabetes Is a Multi-Billion Dollar Market - Big Pharma Have $215 Billion for Licensing New Drug Targets
Upon successful marketing, the potential income to Ventana has been estimated at $ 2.9 billion. | |
Management Team
Ventana Biotech Inc's management team has just the right mix of business experience and knowledge together with cutting edge science:
Janne Christensen, President of Ventana Biotech Inc-- has many years experience working with numerous biotech and medical appliance companies, providing independent consulting services in the field of international business development. Her many clients included Ambu, Comlic, and Tcelic. In October 2008, she became the President of Ventana Biotech Inc, a European based, development stage biotech company.
Young Keun Yoon, Director is a specialist in IP, patents and research and has done an amazing job of keeping Ventana ahead of the competition by keeping Ventana's targets the most promising within the appetite suppressant industry, Young Keun is also focused on business development and negotiating future agreements for licensing of the Company's IP and patents.
Professor Vijay Guptha - Molecular biologist with advanced degrees from the university of Bangalore, the University of Birmingham, as well as a PhD in biochemistry from the Stanford School of Medicine, Mr. Guptha has extensive nutritional and pharmaceutical experience having worked for the Beecham Group and later for SmithKline Beecham. Professor Guptha holds lectures in medicine and molecular biology at universities in India, and he serves as an advisor for companies all over the world.
Mr. Guptha will contribute his expertise and pharmaceutical experience to Ventana's business of sourcing and analyzing new anti-obesity drug targets, and identifying lucrative distribution channels for its patents.
|
Investor relations  http://www.ventanabiotech.com Ventana's proprietary chewing gum contains an extract of hoodia gordonii and 2-hydroxyoleic acid. Ventana Biotech Inc is developing a appetite-suppressing chewing gum. The active ingredients in the plant extracts are released into the patient's blood stream, and trigger a hormonal response in the part of the brain (the hypothalamus) that tells the body it is "full", thereby suppressing the appetite of the obese patient. Because the plant extracts activate hormones that naturally exist in the body, there are no harmful side effects.
With Ventana's proprietary Anti-Obesity Chewing Gum, users can safely control their appetites. Early indications show the Gum is able to reduce appetite by between 15 and 25 percent. Ventana continues to perfect this promising biotechnology and plans to eventually out-license it to Big Pharma companies. The Ventana Biotech Inc information sheet The Ventana Biotech Bull report   Ventana Biotech Inc and Prime Bioresearch recently signed an Official Letter of Intent to Collaborate, which confirmed Prime Bioresearch’s intent to enter a full collaboration agreement with Ventana by the end of this quarter.
Ventana will partner with Prime Bioresearch for the project management and outsourcing of the Research and Development for its patented Anti-Obesity Chewing Gum. The two companies are considering collaboration agreements for Ventana’s future patents as well. Read 
Prime Bioresearch is an experienced drug target acquisition and development company that specializes in developing medicines for markets such as Obesity and Type 2 Diabetes.
 THE PBR INFORMATION SHEET |
All Recent News
10 August 2009Ventana Biotech Inc. (”Ventana”) (VNTA.PK), a biotechnology company developing an appetite-suppressing chewing gum, today revealed its latest groundbreaking research in tackling yet another of the modern lifestyle-induced illnesses: Stress!...Read 
Patents Journal database:
Publication
Date | Application
Number | Details
|
29 July 2009
(Journal 6271) | GB0910102.3 | Applicants: Jenson, Anders and Ventana Biotech Inc
Title: Chewing gum compositions comprising 2-hydroxyoleic acid and extracts of hoodia gordonii having appetite suppressant activity
Date Lodged: 12 June 2009 |
Publication
Date | Application
Number | Details
|
07 October 2009
(Journal 6281) | GB0915414.7 | Applicant: Ventana Biotech Inc
Title: Chewing gum compositions comprising extracts of albizia julibrissin and rhodiola rosea having stress reliving activity
Date Lodged: 4 September 2009 |
News and Media for Ventana Biotech Inc. (VNTA)
Knobias Headlines for Ventana Biotech Inc. (VNTA)
Depth/Level II for Ventana Biotech Inc. (VNTA)
=============================================================
Related companies:
Related videos:
Hoodia Gordonii on 60 Minutes Hoodia Online/Hoodia Gordonii EPR HOODIA LOSE Hoodia Gordonii Cactus & Hollywood
Projections
Welcome to